Plasma apolipoprotein AI (apoAI) and lecithin-cholesterolThe secretion of apoAI or LCAT by transduced cultures acyltransferase (LCAT) play important roles in reverse was two-to five-fold higher using AAV-based plasmid veccholesterol transport, promoting the removal of excess tors than conventional plasmid vectors. Additionally, cells cholesterol from peripheral cells and reducing formation of transfected with a bicistronic AAV-based vector containing atherosclerotic lesions. Gene augmentation of either apoAI an internal ribosome entry site (IRES) efficiently expressed or LCAT, or both, are thus attractive targets for prevention both apoAI and LCAT simultaneously. Furthermore, AAVor treatment of atherosclerosis. With the eventual aim of based vector sequences were retained by host cells, safe and efficient gene delivery to skeletal muscle, our whereas those of conventional plasmid vectors were lost. chosen secretory platform for systemic delivery of antiThese studies indicate that ectopic overexpression of atherogenic proteins, we have constructed conventional apoAI and LCAT in muscle tissue using AAV-based and AAV-based plasmid vectors containing human apoAI plasmid vectors might provide a feasible anti-atherogenic or LCAT cDNAs; their efficacy was tested by lipoplex transstrategy in vivo. fection of mouse C2C12 muscle cells or human 293 cells.